NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Invasive Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

HISTOLOGY

HORMONE RECEPTOR STATUS

HER2 STATUS

SYSTEMIC ADJUVANT TREATMENT

See Systemic Adjuvant Treatment - Hormone Receptor Positive - HER2-Positive Disease (BINV-5)

HER2-positive b

ER positive and/or PR positive

See Systemic Adjuvant Treatment - Hormone Receptor Positive - HER2-Negative Disease (BINV-6)

HER2-negative b

• Ductal u • Lobular • Mixed • Metaplastic

See Systemic Adjuvant Treatment - Hormone Receptor Negative - HER2-Positive Disease (BINV-7)

HER2-positive b

ER negative and PR negative

See Systemic Adjuvant Treatment - Hormone Receptor Negative - HER2-Negative Disease (BINV-8)

HER2-negative b

ER positive and/or PR positive

• Tubular • Mucinous

See Systemic Adjuvant Treatment - Favorable Histologies (BINV-9)

ER negative and PR negative

b See Principles of HER2 Testing (BINV-A) . u This includes medullary and micropapillary subtypes.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

BINV-4

Version2.2015, 03/11/2015© National Comprehensive Cancer Network, Inc. 2015,All rights reserved.The NCCN Guidelines ® and this illustration may not be reproduced in any form without the express written permission of NCCN ® .